Premium
Does progress achieved in the treatment of patients with metastatic non‐small‐cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
Author(s) -
Schmid Sabine,
Suipyte Jorune,
Herrmann Christian,
Mousavi Mohsen,
Hitz Felicitas,
Früh Martin
Publication year - 2020
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.13206
Subject(s) - medicine , lung cancer , cancer registry , cohort , cancer , population , cohort study , young adult , environmental health
Objective Treatment options for non‐small‐cell lung cancer (NSCLC) have been evolving. The goal of our study was to evaluate whether novel therapeutics are used in the elderly population and improve outcomes to a similar extent as in young patients. Methods We enrolled patients registered in the Cancer Registry of Eastern Switzerland and grouped them into four cohorts: Elderly patients aged ≥70 years diagnosed 2005–2007 and 2015–2016 (elderly cohorts 1,2) were compared to cohorts of patients < 70 years diagnosed during the same time periods (young cohorts 1,2). Results 499 individuals were analysed. Median cancer‐specific survival in the elderly cohorts 1 and 2 was 3.9 months and 6.3 months, respectively, and 8.0 and 12.7 months in the young cohorts 1 and 2. 12‐month survival significantly improved over ten years only in younger patients (35.6% and 54.9%), however not in the elderly cohorts (20% vs. 35%). Proportion of patients receiving any line of systemic treatment remained lower in the elderly cohorts (53% vs. 78%). Conclusion Despite the increase in median cancer‐specific survival in both cohorts, a significant and clinically meaningful improvement of 12‐month cancer‐specific survival was only seen in young patients. The adoption of novel treatment approaches is lagging behind in the elderly population.